[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562249":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":11,"studyPopulation":11,"armGroups":42,"interventions":53,"overallOfficials":61,"centralContacts":66,"locations":11,"responsibleParty":72,"collaborators":74,"id":78,"slug":11,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":11,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":11,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":97,"whyStopped":11,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":11},{"fullName":5,"class":6},"Johns Hopkins Bloomberg School of Public Health","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Days of Cryptosporidium-associated diarrhea",null,"7 days",{"measure":14,"description":15,"timeFrame":16},"Time to clearance of Cryptosporidium from stool","Measured in days","6 months",[18,20,22,26,28],{"measure":19,"description":11,"timeFrame":16},"Adverse events, total and stratified by age",{"measure":21,"description":15,"timeFrame":16},"Time-to-first Cryptosporidium infection in sibling",{"measure":23,"description":24,"timeFrame":25},"Change in weight from baseline to 6 months post-treatment","Weight measured in kilograms","Baseline, 6 months",{"measure":27,"description":11,"timeFrame":25},"Change in Lactulose:Mannitol ratio from baseline to 6 months post treatment",{"measure":29,"description":30,"timeFrame":25},"Change in height-for-age adjusted z-score from baseline to 6 months post treatment","Measured in centimeters",{"allocation":32,"interventionModel":33,"interventionModelDescription":11,"primaryPurpose":34,"observationalModel":11,"timePerspective":11,"maskingInfo":35},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":36,"maskingDescription":11,"whoMasked":37},"QUADRUPLE",[38,39,40,41],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[43,48],{"label":44,"type":45,"description":11,"interventionNames":46},"Nitazoxanide","EXPERIMENTAL",[47],"Drug: Nitazoxanide",{"label":49,"type":50,"description":11,"interventionNames":51},"Placebo","PLACEBO_COMPARATOR",[52],"Drug: Placebo",[54,58],{"type":55,"name":44,"description":56,"armGroupLabels":57,"otherNames":11},"DRUG","5 mL suspension (100 mg), 2x\u002Fday for 3 days",[44],{"type":55,"name":49,"description":59,"armGroupLabels":60,"otherNames":11},"identical in consistency, appearance, and taste to nitazoxanide suspension. 5 mL suspension given 2x\u002Fday for 3 days",[49],[62],{"name":63,"affiliation":64,"role":65},"Poonum Korpe, MD","Johns Hopkins University","PRINCIPAL_INVESTIGATOR",[67],{"name":68,"role":69,"phone":70,"phoneExt":11,"email":71},"Poonum S Korpe, MD","CONTACT","7037254821","pkorpe1@jhu.edu",{"type":73,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[75],{"name":76,"class":77},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH","100562249",false,"NCT06600711","Nitazoxanide for Treatment of Cryptosporidium in Children","Randomized Control Trial of Nitazoxanide for the Treatment of Cryptosporidium Infection in Malnourished Children in Bangladesh","Inclusion Criteria:\n\n* tests positive for Cryptosporidium by stool point-of-care test, with or without active diarrhea\n* family plans on remaining in the area for next 6 months\n\nExclusion Criteria:\n\n* history of hypersensitivity to nitazoxanide.\n* taking warfarin. Tizoxanide, the metabolite of nitazoxanide is highly bound to plasma proteins and may compete with binding sites of other highly plasma bound drugs with narrow therapeutic indices, including warfarin.\n* history of renal insufficiency or a baseline serum creatinine = 40 µmol\u002FL. Renal clearance of the drug has not been studied.\n* history of hepatic dysfunction or serum aspartate aminotransferase (AST) ;\n* 50 U\u002FL, serum alanine transaminase (ATL) ;\n* 50 U\u002FL, or serum bilirubin ;\n* 23 µmol\u002FL. Hepatic clearance of the drug has not been studied.","ALL","6 Months","12 Months",{"count":88,"type":89},480,"ESTIMATED","INTERVENTIONAL",[92],"PHASE3","The goal of this clinical trial is to learn if nitazoxanide (NTZ) can treat Cryptosporidium infection in children age 6-12 months. The main questions it aims to answer are:\n\n* Does NTZ treatment of diarrheal Cryptosporidium infection lower the number of days of diarrhea?\n* Does NTZ treatment of diarrheal and non-diarrheal Cryptosporidium infection lower the number of days that parasites can be found in the stool?\n\nResearchers will compare NTZ to a placebo (a look-alike substance that contains no drug) to see if NTZ works to treat Cryptosporidium.\n\nParticipants will:\n\n* Take NTZ or placebo for 3 days\n* Receive regular visits from field research assistants\n* Provide blood and urine samples",[95],"Cryptosporidiosis",[44],"NOT_YET_RECRUITING","2026-04-16",{"date":100,"type":101},"2026-04-17","ACTUAL",{"date":103,"type":89},"2026-06-30",{"date":105,"type":89},"2030-05",{"name":5,"class":6}]